BBA
VYGR icon

Baker Bros. Advisors’s Voyager Therapeutics VYGR Stock Holding History

Baker Bros. Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-237,014
Closed -$4.88M – 124
2017
Q3 		$4.88M Buy
+237,014
New +$2.67M 0.04% 78

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Baker Bros. Advisors's VYGR Position: Q4 2017 in Review

Baker Bros. Advisors sold out of Voyager Therapeutics (VYGR) in Q4 2017, closing a stake of 237,014 shares — an estimated $4.88M sold.

Baker Bros. Advisors first reported a position in VYGR in Q3 2017 and held it in 1 quarter. The position peaked at $4.88M in Q3 2017. 98 funds tracked by Wall St. Rank hold VYGR as of Q4 2017.

  • Baker Bros. Advisors reported no remaining Voyager Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Baker Bros. Advisors sold 237,014 Voyager Therapeutics shares in Q4 2017, an estimated $4.88M.
  • Baker Bros. Advisors first reported a position in Voyager Therapeutics in Q3 2017 and held it in 1 quarter.
  • Baker Bros. Advisors's Voyager Therapeutics position peaked at $4.88M in Q3 2017.
  • 98 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2017.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.